鉄マンガン剤硫酸化ジルコニアナノ粒子の細胞毒性と物理化学的特性

ルイスとブレンステッドの両方の酸性部位を備えた鉄マンガンドープ硫酸化ジルコニアナノ粒子は、熱水妊娠法によって調製され、その後650°Cで5時間焼成し、癌細胞株に対する細胞毒性特性が決定されました。特性評価は、X線回折、熱重量分析、フーリエ変換赤外線分光法、ブラウナー - エメットテラー（BET）表面積測定、X線蛍光、X線光電子分光法、ゼータサイズ電位、および透過型電子顕微鏡（TEM）を使用して実行されました。The cytotoxicity of iron-manganese-doped sulfated zirconia nanoparticles was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays against three human cancer cell lines (breast cancer MDA-MB231 cells, colon carcinoma HT29 cells, and hepatocellular carcinoma HepG2細胞）および2つの正常なヒト細胞株（正常な肝細胞チャン細胞と正常なヒト臍静脈内皮細胞[Huvecs]）。結果は、鉄マンガン型硫酸化ジルコニアナノ粒子がMDA-MB231およびHEPG2癌細胞に対して細胞毒性であるが、7.8μg/mLから500μg/mLの濃度でHT29および正常細胞に対する毒性が少ないことを初めて示唆しています。処理された細胞の形態も研究され、結果は、ナノ粒子処理HEPG2およびMDA-MB231細胞がHT29細胞よりも細胞形態の劇的な変化を示したという点で、細胞毒性研究の結果を支持しました。この方法で、この研究は、健康な細胞機能に有害な影響を及ぼさずに、広範囲のがんアプリケーションについて、鉄マンガン型硫酸化ジルコニアナノ粒子をさらに研究すべきであるという最初の証拠を提供します。

Iron-manganese-doped sulfated zirconia nanoparticles with both Lewis and Brønsted acidic sites were prepared by a hydrothermal impregnation method followed by calcination at 650°C for 5 hours, and their cytotoxicity properties against cancer cell lines were determined. The characterization was carried out using X-ray diffraction, thermogravimetric analysis, Fourier transform infrared spectroscopy, Brauner-Emmett-Teller (BET) surface area measurements, X-ray fluorescence, X-ray photoelectron spectroscopy, zeta size potential, and transmission electron microscopy (TEM). The cytotoxicity of iron-manganese-doped sulfated zirconia nanoparticles was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays against three human cancer cell lines (breast cancer MDA-MB231 cells, colon carcinoma HT29 cells, and hepatocellular carcinoma HepG2 cells) and two normal human cell lines (normal hepatocyte Chang cells and normal human umbilical vein endothelial cells [HUVECs]). The results suggest for the first time that iron-manganese-doped sulfated zirconia nanoparticles are cytotoxic to MDA-MB231 and HepG2 cancer cells but have less toxicity to HT29 and normal cells at concentrations from 7.8 μg/mL to 500 μg/mL. The morphology of the treated cells was also studied, and the results supported those from the cytotoxicity study in that the nanoparticle-treated HepG2 and MDA-MB231 cells had more dramatic changes in cell morphology than the HT29 cells. In this manner, this study provides the first evidence that iron-manganese-doped sulfated zirconia nanoparticles should be further studied for a wide range of cancer applications without detrimental effects on healthy cell functions.